Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

The stock's fall snapped a three-day winning streak.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.